Literature DB >> 15147316

Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer's disease in aged mice.

Masaoki Kawasumi1, Tomohiro Chiba, Marina Yamada, Makiko Miyamae-Kaneko, Masaaki Matsuoka, Jin Nakahara, Taisuke Tomita, Takeshi Iwatsubo, Shigeaki Kato, Sadakazu Aiso, Ikuo Nishimoto, Keisuke Kouyama.   

Abstract

While the exact aetiology of Alzheimer's disease (AD) is unknown, distinct genetic mutations have been identified for the rare cases of familial AD (FAD). V642I mutation in amyloid precursor protein (APP) co-segregates with FAD with perfect penetration, and the clinicopathological characteristics of patients with this mutation resemble that of sporadic AD. To examine the pathogenic process of this FAD-linked trait in vivo, we produced a mouse with the corresponding point mutation in the APP gene using homologous recombination and Cre-loxP site-specific recombination ('knock-in' technique). Mice with the heterozygous V642I-APP allele most precisely reflected the genotype of humans bearing this mutation. For the observation period of 2.5 years the mutants stayed apparently indistinguishable from the wild-type littermates. However, behavioural analysis revealed significantly deteriorated long-term memory in mutants when examined for the retention of spatial attention. Interestingly, acquisition of spatial memory was slightly affected but short-term working memory was not deteriorated at all. Histological examination was negative for formation of neuritic plaques or neurofibrillary tangles, whereas the relative amount of longer form of beta-amyloid species A beta 42(43) was significantly increased against that of the shorter form (A beta 40) in the mutant brain homogenates. We conclude that a V642I-APP mutant allele in aged mice confers functional components, but not organic components, of the AD-related phenotype that are observed in the early stage of AD. This V642I-APP knock-in mutant line may serve as a model to study the early pathogenic processes of AD in vivo and to develop therapeutics for this stage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147316     DOI: 10.1111/j.0953-816X.2004.03397.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  19 in total

Review 1.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

2.  Dopamine Burden Triggers Neurodegeneration via Production and Release of TNF-α from Astrocytes in Minimal Hepatic Encephalopathy.

Authors:  Saidan Ding; Weikan Wang; Xuebao Wang; Yong Liang; Leping Liu; Yiru Ye; Jianjing Yang; Hongchang Gao; Qichuan Zhuge
Journal:  Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.590

3.  The Involvement of the Decrease of Astrocytic Wnt5a in the Cognitive Decline in Minimal Hepatic Encephalopathy.

Authors:  Saidan Ding; Zhu Xu; Jianjing Yang; Leping Liu; Xueli Huang; Xuebao Wang; Qichuan Zhuge
Journal:  Mol Neurobiol       Date:  2016-11-22       Impact factor: 5.590

Review 4.  APP physiological and pathophysiological functions: insights from animal models.

Authors:  Qinxi Guo; Zilai Wang; Hongmei Li; Mary Wiese; Hui Zheng
Journal:  Cell Res       Date:  2011-07-19       Impact factor: 25.617

5.  Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.

Authors:  Jessica Ciesler; Youssef Sari
Journal:  Open J Neurosci       Date:  2013-04-08

6.  Transforming growth factor beta2 is a neuronal death-inducing ligand for amyloid-beta precursor protein.

Authors:  Yuichi Hashimoto; Tomohiro Chiba; Marina Yamada; Mikiro Nawa; Kohsuke Kanekura; Hiroaki Suzuki; Kenzo Terashita; Sadakazu Aiso; Ikuo Nishimoto; Masaaki Matsuoka
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

Review 7.  Vaccination strategies for Alzheimer's disease: A new hope?

Authors:  Adele Woodhouse; Tracey C Dickson; James C Vickers
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 8.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

Review 9.  Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection.

Authors:  Steven D Buckingham; Andrew K Jones; Laurence A Brown; David B Sattelle
Journal:  Pharmacol Rev       Date:  2009-03-16       Impact factor: 25.468

Review 10.  Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products.

Authors:  Mohammad Amjad Kamal; Muneeb U Rehman; Mashoque Ahmad Rather; Andleeb Khan; Saeed Alshahrani; Hina Rashid; Marwa Qadri; Summya Rashid; Rana M Alsaffar
Journal:  Mediators Inflamm       Date:  2021-07-31       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.